Adage Capital Partners’s Blueprint Medicines BPMC Stock Holding History

Adage Capital Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$6.41M	–	895
2025 Q2	$6.41M	Buy	+50,000	New	+$5.19M	0.01%	678
2024 Q1	–	Sell	-36,000	Closed	-$3.32M	–	879
2023 Q4	$3.32M	Buy	+36,000	New	+$2.33M	0.01%	718
2023 Q3	–	Sell	-32,903	Closed	-$2.08M	–	875
2023 Q2	$2.08M	Buy	+32,903	New	+$1.79M	﹤0.01%	740

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Adage Capital Partners's BPMC Position: Q3 2025 in Review

Adage Capital Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 50,000 shares — an estimated $6.41M sold.

Adage Capital Partners first reported a position in BPMC in Q2 2023 and held it in 3 quarters. The position peaked at $6.41M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Adage Capital Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Adage Capital Partners sold 50,000 Blueprint Medicines shares in Q3 2025, an estimated $6.41M.
Adage Capital Partners first reported a position in Blueprint Medicines in Q2 2023 and held it in 3 quarters.
Adage Capital Partners's Blueprint Medicines position peaked at $6.41M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.